Company news
Cipher Pharmaceuticals Inc. (TSX:CPH) news
Every Cipher Pharmaceuticals Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Cipher Pharmaceuticals Reports Second Quarter 2026 Results
August 11, 2026
Cipher Pharmaceuticals Schedules Q2 2026 Earnings Release and Conference Call
July 31, 2026
Cipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris®
July 6, 2026
Cipher Pharmaceuticals Announces Results of Annual General Meeting of Shareholders
June 18, 2026
Cipher Pharmaceuticals Reports First Quarter Results
May 7, 2026
Cipher Pharmaceuticals Schedules Q1 2026 Earnings Release and Conference Call
April 29, 2026
Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings
March 12, 2026
Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call
March 4, 2026
Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™ (Spinosad)
January 28, 2026
Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba(TM) (Spinosad)
January 28, 2026
Cipher Pharmaceuticals Reports Third Quarter 2025 Results
November 6, 2025
Cipher Pharmaceuticals Schedules Q3 2025 Earnings Release and Conference Call
October 29, 2025
Cipher Pharmaceuticals Receives Successful Arbitration Award
October 14, 2025
Cipher Pharmaceuticals Announces the Passing of Director Mr. Harold Wolkin
August 26, 2025
Cipher Pharmaceuticals Reports Second Quarter 2025 Results, Including Record Revenue
August 7, 2025
Cipher Pharmaceuticals Schedules Q2 2025 Earnings Release and Conference Call
July 29, 2025
Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders
June 13, 2025
Cipher Pharmaceuticals Reports First Quarter 2025 Results, and Announces $15 Million Debt Repayment
May 8, 2025
Cipher Pharmaceuticals Schedules Q1 2025 Earnings Release and Conference Call
May 2, 2025
Cipher Pharmaceuticals Announces Normal Course Issuer Bid, Including Intention to Utilize Block Purchases
May 1, 2025
Cipher Pharmaceuticals Secures Medicaid Step-Through Preferred Status for Natroba™ in the state of Illinois
April 29, 2025
Cipher Pharmaceuticals Secures Medicaid Step-Through Preferred Status for Natroba(TM) in the state of Illinois
April 29, 2025
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results
March 18, 2025
Cipher Pharmaceuticals Schedules Q4 & Fiscal 2024 Earnings Release and Conference Call
March 11, 2025
Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 Study
December 10, 2024
Cipher Pharmaceuticals Reports Third Quarter 2024 Results
November 7, 2024
Cipher Pharmaceuticals Schedules Q3 2024 Earnings Release and Conference Call
November 4, 2024
Cipher Pharmaceuticals Enhances Leadership Team with Appointment of New Chief Business Officer
October 8, 2024
Keynotes and 50 Companies to Present at the Planet MicroCap Showcase: VANCOUVER in association with Small Cap Discoveries on September 25...
September 24, 2024
Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study
September 13, 2024
Canadian Investment Regulatory Organization Trade Resumption - CPH
September 13, 2024
Canadian Investment Regulatory Organization Trading Halt - CPH
September 13, 2024
Cipher Pharmaceuticals Reports Second Quarter 2024 Results
August 8, 2024
Cipher Pharmaceuticals Schedules Q2 2024 Earnings Release and Conference Call
August 1, 2024
Cipher Pharmaceuticals Acquires Profitable Growth Dermatology Products from ParaPRO for US$89.5 Million
July 29, 2024
Cipher Pharmaceuticals Reports First Quarter 2024 Results
May 9, 2024
Cipher Pharmaceuticals Schedules Q1 2024 Earnings Release and Conference Call
May 3, 2024
Cipher Pharmaceuticals Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference
April 3, 2024
Cipher Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results
March 14, 2024
Cipher Pharmaceuticals Schedules Q4 2023 Earnings Release and Conference Call
March 8, 2024
Cipher Pharmaceuticals Announces the Commencement of OTCQX Trading
January 29, 2024
Cipher Pharmaceuticals Announces Change of Auditor
November 24, 2023
Cipher Pharmaceuticals Announces Normal Course Issuer Bid
November 15, 2023
Cipher Pharmaceuticals Reports Strong Sales & Earnings Growth in Q3 2023
November 9, 2023
Cipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference Call
October 27, 2023
Cipher Pharmaceuticals Announces Final Results of Substantial Issuer Bid
October 12, 2023
Cipher Pharmaceuticals Provides Reminder of the Upcoming Expiration of its Substantial Issuer Bid
October 3, 2023
Cipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian Dollars
September 5, 2023
Cipher Pharmaceuticals Releases Q2 2023 Results, Announces Launch of Epuris in Mexico
August 10, 2023
Cipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference Call
July 28, 2023